PT  - JOURNAL ARTICLE
AU  - Simon, David
AU  - Tascilar, Koray
AU  - Fagni, Filippo
AU  - Schmidt, Katja
AU  - Krönke, Gerhard
AU  - Kleyer, Arnd
AU  - Ramming, Andreas
AU  - Schoenau, Verena
AU  - Bohr, Daniela
AU  - Knitza, Johannes
AU  - Harrer, Thomas
AU  - Manger, Karin
AU  - Manger, Bernhard
AU  - Schett, Georg
TI  - Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease
AID  - 10.1136/annrheumdis-2021-221554
DP  - 2022 Jul 01
TA  - Annals of the Rheumatic Diseases
PG  - 1023--1027
VI  - 81
IP  - 7
4099  - http://ard.bmj.com/content/81/7/1023.short
4100  - http://ard.bmj.com/content/81/7/1023.full
SO  - Ann Rheum Dis2022 Jul 01; 81
AB  - Objectives To test whether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered.Methods Patients with IMID who failed to seroconvert after two doses of SARS-CoV-2 vaccine were subjected to a third vaccination with either mRNA or vector-based vaccines. Anti-SARS-CoV-2 IgG, neutralising activity and T cell responses were assessed at baseline and 3 weeks after revaccination and also evaluated seprarately in rituximab (RTX) and non-RTX exposed patients.Results 66 non-responders were recruited, 33 treated with RTX, and 33 non-exposed to RTX. Overall, 49.2% patients seroconverted and 50.0% developed neutralising antibody activity. Seroconversion (78.8% vs 18.2%) and neutralising activity (80.0% vs 21.9%) was higher in non-RTX than RTX-treated patients with IMID, respectively. Humoral vaccination responses were not different among patients showing positive (59.3%) or negative (49.7%) T cell responses at baseline. Patients remaining on mRNA-based vaccines showed similar vaccination responses compared with those switching to vector-based vaccines.Conclusions Overall, these data strongly argue in favor of a third vaccination in patients with IMID lacking response to standard vaccination irrespective of their B cell status.Data are available on reasonable request. N/A.